Thermo Fisher Scientific Comprehensive Income, Including Noncontrolling Interest decreased by 14.3% to $1.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.3%, from $1.87B to $1.60B.
tmo_comprehensive_income_including_nci| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.76B | $1.88B | $2.20B | $1.29B | $1.29B | $1.34B | $1.49B | $1.59B | $1.79B | $1.90B | $1.57B | $1.87B | $1.60B |
| QoQ Change | — | +6.7% | +17.2% | -41.4% | +0.1% | +3.8% | +10.8% | +6.8% | +12.7% | +6.3% | -17.3% | +18.9% | -14.3% |
| YoY Change | — | — | — | -26.7% | -31.3% | -39.2% | +15.1% | +22.9% | +33.4% | +28.0% | -0.9% | +4.5% | -14.3% |